A new therapeutic approach to treat Alzheimer's disease (AD) is needed, and the use of growth factors is considered to be a candidate. Hepatocyte growth factor (HGF) is a unique multifunctional growth factor, which has the potential effect to exert neurotrophic action and induce angiogenesis. In this study, we examined the effects of overexpression of human HGF plasmid DNA using ultrasound-mediated gene transfer into the brain in an Ab-infused cognitive dysfunction mouse model. We demonstrated that HGF gene transfer significantly alleviated Ab-induced cognitive impairment in mice in behavioral tests. These beneficial effects of HGF might be due to (1) significant recovery of the vessel density in the dentate gyrus of the hippocampus, (2) upregulation of BDNF, (3) a significant decrease in oxidative stress and (4) synaptic enhancement. A pharmacological approach including gene therapy to increase the HGF level in combination with anti-Ab therapy might be a new therapeutic option for the treatment of AD.
Introduction
Alzheimer's disease (AD), the most common cause of dementia in elderly humans, is characterized by Ab-containing plaques and neurofibrillary tangles in the neocortex and hippocampus, synaptic and neuronal loss along with progressive cognitive impairment. Ab, a 40-42 amino-acid peptide, is the primary component of senile plaques. 1 Ab deposited in senile plaques is considered to be primarily involved in the pathogenesis of AD, because (1) familial AD has been linked to mutations in the amyloid precursor protein (APP) 2 and (2) familial AD-linked mutations in the APP and presenilin genes result in increased production of Ab42, which is the predominant form found in senile plaques. 2 Levels of total Ab40 and Ab42 are elevated early in dementia, and levels of both peptides are strongly correlated with cognitive decline. 3 A new approach is required, because current pharmacological therapy directed at symptomatic relief has proved to be marginally effective. 4 Gene therapy might be one therapeutic option. A growth factor could be such a target gene to be delivered for treatment of AD. 5 Indeed, a phase 1 clinical trial of ex vivo nerve growth factor gene delivery for AD, implanting fibroblasts genetically modified to express nerve growth factor into the forebrain, showed improvement of cognitive decline and increased cortical metabolism. 6 To explore alternative gene therapy to nerve growth factor, we focused on hepatocyte growth factor (HGF), since HGF is a unique growth factor, which was discovered as a regeneration factor for hepatocytes in liver injury. 7 Moreover, HGF is a multifunctional growth factor, which has the potential to exert neurotrophic action 8 and induce angiogenesis. 9 Importantly, in vitro, exogenously applied HGF enhanced synaptic long-term potentiation in the CA1 region of the hippocampus. 10 Our previous in vivo report also demonstrated that overexpression of HGF improved memory and learning after cerebral infarction in rats. 11 In addition, in a neurodegenerative disease, overexpression of HGF retarded disease progression in a transgenic mouse model of amyotrophic lateral sclerosis. 12 Thus, we hypothesized that HGF might improve Ab-induced memory deficit in an Ab injection model in this study.
Results

Ultrasound-mediated gene transfer into cerebral ventricle
Although gene therapy might become an alternative approach for central nervous system diseases, the safety issue is a serious concern in human gene therapy. To overcome this problem, we previously developed an efficient gene transfer method into the adult rat brain based on a microbubble-enhanced ultrasound method using plasmid DNA. 13 In a previous study, we transfected foreign genes by intracisternal or intrastriatal injection. 13 In this study, we modified the previous method to obtain a more effective method. Initially, we examined gene expression of a marker gene, luciferase. Although gene expression without ultrasound was significantly higher than that with control vector at 1 day after gene transfer (Po0.05 vs control; Figures 1a and b), gene transfer with ultrasound resulted in a further increase in expression of the luciferase gene (Po0.05 vs control; Figure 1b) .
We transfected human HGF plasmid DNA with ultrasound, and initially measured human HGF protein by a human-specific enzyme-linked immunosorbent assay. Human HGF protein could be detected at each dose, although there was no significant difference in gene expression level among three doses (Po0.01 vs control; Figure 1c) . Therefore, we chose 20 mg HGF plasmid DNA for our experiments. In the future, it will be necessary to evaluate whether this dose in mice is equivalent to the dose used in a clinical trial for peripheral ischemic vascular disease in humans. Figure 1d ). This phenomenon was consistent with the results of our previous studies showing that exogenously added HGF stimulated the expression of endogenous HGF. 15 Next, to further confirm successful gene transfer, we performed immunohistochemical staining of HGF to evaluate the localization of gene expression in the brain. We detected HGF protein in the injection site and also around the cerebral ventricles (Figure 1e ). We also measured the expression of HGF mRNA by quantitative real-time PCR. The data confirmed that HGF gene transfer increased the expression of human HGF mRNA (Po0.05; Figure 1f ). Consistent with a previous report, 16 mouse HGF mRNA expression was upregulated in mice transfected with the human HGF gene as compared with control vector (Po0.05; Figure 1g ). Moreover, mouse c-Met mRNA was also upregulated in human HGF gene-transferred mice as compared with control vector (Po0.05; Figure 1h ), consistent with a previous report. 17 Upregulation of both HGF and c-Met expression might enhance the signaling of HGF.
Effects of overexpression of HGF in Ab-injected mice
Given the successful gene transfer of HGF, we employed an Ab-injection model 18 to investigate whether gene transfer of HGF ameliorates Ab-induced memory impairment. Intracerebroventricular injection of Ab peptides is known to cause amnesia in rodents, 18 and is useful in evaluating candidate therapy for Ab-related dementia, that is, AD. 18 In the present study, Ab(1-40), one of the major full-length Ab peptides in AD, 1 was injected into the mouse cerebral ventricle, and at 2 weeks after Ab injection, gene transfer of HGF was performed. Then, at 3 weeks after Ab injection, two sets of tests of cognitive function, Y-maze test and water-finding task, were performed (Figure 2a) . Ab(40-1) was used as a control peptide for Ab . In the water-finding task, mice treated with Ab(1-40) showed longer drinking latency than mice treated with Ab(40-1), indicating that Ab(1-40) causes impairment of latent learning in mice (Ab(40-1), n ¼ 21; vector, n ¼ 23; Po0.05; Figure 2b) . Transfection of the control vector did not affect memory impairment. In contrast, mice transfected with the HGF gene demonstrated significantly better performance in the water-finding task than mice transfected with the Figure 2b ). In the training trial, the number of approaches did not vary among groups, suggesting that the opportunity for the mice to learn about the apparatus was not different among the groups (data not shown). In addition, in the Y-maze test, mice treated with Ab(1-40) showed a significantly lower alternation percentage as compared with mice treated with Ab(40-1) (Ab(40-1), n ¼ 21; vector, n ¼ 23; Po0.05; Figure 2c ). Similar to the water-finding task, mice transfected with the HGF gene showed a higher percentage of alternation than mice treated with the control vector (HGF, n ¼ 20; vector, n ¼ 23, Po0.05, Figure 2c ). There was no significant difference in total arm entries among groups, suggesting that the activity of mice was not different among the groups (data not shown). These data suggest that gene transfer of HGF ameliorated Ab-induced memory impairment with respect to both reference/long-term memory and working/short-term spatial memory.
Molecular mechanisms of alleviation of Ab-induced cognitive impairment by HGF gene transfer
Since HGF is also an angiogenic growth factor, 9 we measured the density of vessels in the dentate gyrus of the hippocampus by fluorescein isothiocyanate (FITC)-albumin microangiography, which allows detection of capillary vessels. 19 In this study, we measured the vessel density at four different regions of interest, the ipsilateral and contralateral dentate gyri of the hippocampus to the Ab-injected side, and the ipsilateral and contralateral cortices to the Ab-injected side at 21 days after Ab injection (7 days after gene treatment; Figure 3a ). There was no significant difference in vessel density in the ipsilateral and contralateral cortices among the groups. On the other hand, the vessel density in the dentate gyri of the hippocampus in mice treated with Ab was significantly decreased as compared with that in mice treated with Ab(40-1). Transfection of human HGF cDNA resulted in significant recovery of vessel density in the dentate gyri on both sides of the hippocampus as compared with control vector (Po0.05; Figures 3b and c). Blood flow in the brain of AD patients was found to be decreased in several studies. 20 The recovery of vessel density might cause recovery of blood flow, leading to modification of the cognitive impairment in AD patients.
Next, we focused on oxidative stress, since Ab induced oxidative stress in vivo, in both an Ab injection model 21 and APP transgenic mice. 22 Therefore, we investigated whether overexpression of HGF reduced oxidative stress in this model. Dihydroethidium (DHE) staining, which detects superoxide, was employed to assess oxidative stress. 23 Indeed, we observed that Ab(1-40) induced oxidative stress in the hippocampus at 21 days after Ab injection (Po0.05; Figure 4 ). At 21 days after Ab injection, oxidative stress as assessed by fluorescence intensity was significantly lower in mice transfected with the HGF gene than in mice transfected with control vector, whereas HGF gene transfer significantly attenuated the increase in oxidative stress induced by Ab(1-40) (Po0.05; Figure 4 ). In addition, we measured the phosphorylation of mitogen-activated protein kinase (MAPK) and Akt. However, there was no significant difference in the phosphorylation of MAPK and Akt among the groups (data not shown). In AD patients, loss of cholinergic neurons is one of the characteristic phenomena. In this model, loss of cholinergic neurons was induced by Ab injection. 18 Indeed, we confirmed that injection of Ab(1-40) significantly induced loss of cholinergic neurons in the basal forebrain. However, there was no significant increase in the number of cholinergic neurons in mice transfected with the HGF gene as compared with mice transfected with control vector (data not shown). To explore the mechanism by which cognitive impairment was recovered by HGF, we further evaluated synaptic activity by synaptophysin immunohistochemical staining. Immunoreactivity of synaptophysin in the dentate gyrus was significantly increased in mice transfected with the HGF gene as compared with control vector (Po0.05; Figure 5 ).
Comparison of cognitive function after HGF and BDNF gene transfer
Finally, we compared the effects of overexpression of the HGF gene or brain-derived neurotrophic factor (BDNF) gene, since BDNF is also one of the major factors in the central nervous system 24 and the BDNF/TrkB neurotrophic signaling pathway is reported to be impaired in the frontal cortex and hippocampus in AD. 25 . Similar to HGF, mice transfected with the BDNF gene demonstrated significantly better performance in the waterfinding task than mice transfected with the control vector (vector, n ¼ 15; BDNF 20 mg, n ¼ 18; BDNF 50 mg, n ¼ 17; *Po0.05, **Po0.01; Figure 6a ). Interestingly, mice transfected with HGF gene revealed a higher percentage of alternation than mice transfected with the control vector in the Y-maze test, although overexpression of the BDNF gene did not have such an effect (vector, n ¼ 19; HGF, n ¼ 17; BDNF 20 mg, n ¼ 18; BDNF 50 mg, n ¼ 17; Po0.05; Figure 6b ). Given the superiority of HGF as compared with BDNF, we further explored why HGF has more potent neuroprotective actions. The present study demonstrated that exogenous HGF significantly increased the endogenous BDNF level both at 3 ( Figure 6c ) and 7 ( Figure 6d ) days after transfection (Po0.05). In addition, quantitative real-time PCR demonstrated that BDNF mRNA was increased in mice transfected with the HGF gene, at 2 days after gene transfer (Po0.05; Figure 6e ). More importantly, the present study clearly revealed a marked difference in the endogenous levels of HGF and BDNF in response to Ab. As shown in Figure 7 , HGF was significantly decreased at 7 days after Ab(1-40) injection (Po0.05; Figure 7a ), whereas there was no significant difference in BDNF at 7 days after injection (Figure 7b ). Gene transfer of HGF might act as an exogenous supply to compensate for the decreased endogenous HGF.
Discussion
The present study demonstrated that HGF gene transfer significantly improved Ab-induced cognitive impairment in mice in behavioral tests. These beneficial effects of HGF might be due to (1) significant recovery of vessel density in the dentate gyrus of the hippocampus through an angiogenic property, (2) upregulation of BDNF, (3) a significant decrease in oxidative stress and (4) synaptic enhancement. To elucidate the molecular mechanisms by which HGF improved cognitive dysfunction induced by Ab (1-40) , we initially focused on the angiogenic
property of HGF, since HGF is a potent angiogenic growth factor in vivo. Our present study demonstrated that injection of Ab(1-40) significantly decreased the vessel density in the dentate gyrus of the hippocampus.
This finding is consistent with the previous observation that Ab peptides reduced cerebral blood flow and functional hyperemia. 26 Moreover, age-dependent cerebrovascular abnormalities and blood flow disturbances 27 In contrast, overexpression of HGF increased the vessel density, consistent with a previous report that overexpression of HGF increased vessel density in the rat brain. 15 The significant reduction of oxidative stress by HGF in the dentate gyrus of the hippocampus is also interesting. Oxidative stress is thought to damage DNA and to be an initiator of neuronal apoptotic cell death. 28 Ab stimulates oxidation through neuronal production of the reactive oxygen species . 29 In addition, many antioxidants have been reported to prevent AD. 30 HGF is reported to phosphorylate Akt, and blockade of Akt activation with the phosphatidylinositol-3 kinase (PI3-K) inhibitor, LY294002, inhibited the survival response in maturing sympathetic neurons by HGF. 31 HGF also prevented hippocampal cell death in rats with transient forebrain ischemia 32 through phosphorylation of extracellular signal-regulated kinase. Since PI3-K/Akt inhibits reactive oxygen species production through rac1, 32,33 HGF might reduce oxidative stress through the PI3-K/Akt pathway. In this study, we also evaluated the phosphorylation of Akt and MAPK by western blotting. However, there was no significant difference among the groups (data not shown). In addition, phosphorylation of CREB (cAMP responsive element binding protein), which decreased neurotoxicity and oxidative stress, 34 might contribute to the decrease in oxidative stress by HGF, as both PI3-K and MAPK phosphorylated CREB. 35, 36 In addition, we found that synaptophysin immunoreactivity in the dentate gyrus was significantly increased in mice transfected with the HGF gene as compared with the control vector. Augmented synaptophysin immunoreactivity would lead to an increase in the number of vesicles and synapses, as shown by electron microscopy. 37, 38 In this study, we employed two evaluation tests, Y-maze test and water-finding task, since the Y-maze test evaluates working memory and the water-finding task evaluates reference memory. Using these two tests, we compared the beneficial effects of HGF and BDNF, since serum BDNF level increases in the early stages of AD and then decreases during the course of the disease, correlating with the severity of dementia. 39 One of the important findings was that mice transfected with the HGF gene showed better performance in cognitive function as assessed by the Y-maze test, whereas the water-finding task did not show any difference between HGF and BDNF. It is noteworthy that HGF improved both working memory and reference memory, whereas BDNF improved only reference memory. These differences might be explained by the previous observation that in human subjects, the BDNF V166M polymorphism is implicated in episodic memory and hippocampal activation, 40 but is not associated with variation in working memory. 41 In contrast, HGF significantly enhanced synaptic long-term potentiation in the CA1 region of the hippocampus. 10 Indeed, we previously reported that HGF significantly improved memory and learning after cerebral infarction in rats. 11 Another possible explanation is the increase in endogenous BDNF induced by exogenously added As previous studies demonstrated that calcium influx increases BDNF mRNA level by activating CREB, 42 activation of CREB through PI3-K-and extracellular signal-regulated kinase-dependent pathways induced by HGF may directly upregulate BDNF. A decrease in endogenous HGF may also explain the beneficial effects of HGF to improve cognitive dysfunction. In AD cases, HGF was immunostained near both astrocytes and microglial cells. 43 Astrocytes expressed HGF 43 , and HGF induced actin reorganization and chemokinesis in astrocytes. 44 As astrocytes play an important role in central nervous system regeneration, 45 HGF may have more potent neuroprotective actions. Indeed, HGF facilitated astrocytosis in the subacute stage and improved learning and memory in the chronic stage of cerebral infarction. 11 In a previous report, HGF concentration was reported to be increased in the cerebrospinal fluid of AD patients. 43 The authors suggested that the increase in cerebrospinal fluid HGF corresponded to white matter damage. In contrast, HGF level in the brain was decreased after Ab(1-40) injection in our model. Since AD is a chronic progressive disease, cells in the white matter are damaged over a long period in the AD brain. The increase in HGF level might be a response to such damage. Moreover, it is necessary to measure expression of the HGF receptor, c-Met, in the brain of an AD mouse model to identify the potential target region in the brain for this therapy.
In conclusion, HGF significantly improved Ab-induced memory impairment in mice, associated with a significant increase in vessel density and BDNF, and a significant decrease in oxidative stress. Further studies are still required to investigate the difference in efficacy and mechanism between HGF and BDNF gene transfer. The pathology of AD includes various properties such as Ab deposition, neurofibrillary tangles, synaptic loss, neuronal cell death and a decrease of blood flow. Therefore, treatment with a single growth factor or single neurotrophic factor might not cure AD. However, a combination of therapies, such as a trophic factor and anti-Ab therapy, could be curative for AD. A pharmacological approach including gene therapy to increase the HGF level in combination with anti-Ab therapy might be a new therapeutic option for treating AD.
Methods
Peptides
Ab(1-40) was obtained from Peptide Institute (Osaka, Japan). Ab(1À40) solution was freshly prepared for each experiment as described previously. 46 Briefly, 0.55 mg Ab(1À40) peptide was dissolved in 3250 ml phosphatebuffered saline with 35% acetonitrile and 0.1% trifluoroacetate. To remove the remaining undissolved Ab(1À40), centrifugation was performed at 15 000 g for 3 min before Ab(1À40) solution was aliquoted. The control peptide Ab(40-1) was also prepared in the same way as Ab(1À40).
Ab injection model
Male ddY mice (6-8 weeks old) were obtained from CLEA Japan. Intracerebroventricular administration was carried out in accordance with the procedure previously described. 18 Briefly, mice were anesthetized with isoflurane gas and xylazine and ketamine, and Ab(1-40) (200 pmol per 5 ml) was injected intracerebroventricularlly into mice, aimed at 1-1.5 mm lateral to the left of the midline, 0.5 mm posterior to the bregma and 3 mm depth using a 100-ml Hamilton syringe with a 27-gauge needle.
Construction of plasmids and ultrasound-mediated gene transfer
For luciferase assay, the luciferase gene (735 bp) was inserted into pcDNA3.1(+). To generate an HGF expression vector, human HGF cDNA (2.2 kb) was inserted into a simple eukaryotic expression plasmid that uses the cytomegalovirus promoter/enhancer. 47 This promoter/ enhancer has been used to express reporter genes in a variety of cell types and can be considered constitutive. The control vector had the same structure as the expression vector plasmid, including the promoter/ enhancer but not containing HGF cDNA. Plasmids were purified with a Qiagen plasmid isolation kit (Qiagen, Valencia, CA, USA). Human BDNF cDNA (1.59 kb) was inserted into the same plasmid vector.
A plasmid containing human HGF cDNA was prepared at 10 mg ml À1 with Milli-Q water, and a plasmid containing human BDNF cDNA was prepared at 10 or 25 mg ml À1 with Milli-Q water. Then, 2 ml plasmid solution containing human HGF cDNA or human BDNF cDNA was suspended with 1.25 ml Optison (ultrasound contrast medium; Mallinckrodt Inc., Hazelwood, MO, USA) and 1.75 ml TE. Two weeks after Ab(1-40) injection into the cerebral ventricle, the plasmid mixture was injected into the cerebral ventricle, aimed at 1-1.5 mm lateral to the right of the midline, 0.5 mm posterior to the bregma and 3 mm depth using a 100-ml Hamilton syringe with a 27-gauge needle. After plasmid mixture injection, ultrasound irradiation (2.0 W cm À2 , 5 s) was applied to each mouse at the injection site. We used a sonoporation gene transfection system (ST2000V; NEPA GENE, Chiba, Japan) with a probe 6 mm in diameter. 
Assay for luciferase activity
For luciferase assay, mice were killed under anesthesia 1, 2 or 7 days after transfection of the luciferase gene. Samples for protein assay were obtained from the whole brain. Luciferase activity was measured using a luciferase assay kit (Promega, Madison, WI, USA), according to the manufacturer's instructions.
Y-maze test
One week after administration of plasmid containing human HGF cDNA, the Y-maze test was carried out as described previously. 48 Briefly, the Y-maze consisted of three arms. Each arm was 40 cm long, the cross-section was trapezoidal in shape, the top was 10 cm wide, the bottom was 3 cm wide and the height was 12 cm. 48 Each mouse was placed at the end of one arm and allowed to explore the Y-maze freely for 8 min, and the series of arm entries was recorded to evaluate short-term/spatial working memory by spontaneous alternation behavior. Spontaneous alternation behavior is based upon the behavior of animals in preferring to choose newer locations. When mice chose a third arm different from the previous two in three consecutive arm choices in the Y-maze, mice were considered to have carried out actual alternation. Alternation behavior was calculated as the percentage of actual alternations to maximum alternations, defined as the total number of arm entries minus two. The number of total arm entries was counted as a locomotion index.
Water-finding task
Water-finding task was carried out 1 week after gene transfer, according to the method described previously. 48 Briefly, the apparatus consisted of an open field (50 Â 30 cm with walls 15 cm high) with an alcove (10 Â 10 Â 10 cm) in the middle of one of the longer sides of the wall. A water bottle with a tube tip was inserted into the ceiling of the alcove. In the training trial, mice were placed individually in one corner of the opposite side of the alcove and allowed to explore freely for 3 min. The frequency of touching, sniffing or licking the water tube in the alcove (the number of approaches) was counted. Mice that could not find the water tube within 3 min were excluded from the test. The mice were immediately returned to their home cages after the training trial, and were then deprived of water for 48 h to motivate them to look for water. In the retention trial, the mice were placed individually in the same corner of the apparatus. To evaluate memory acquisition, drinking latency was measured as the time from the starting corner to their first touch of the water tube.
Evaluation of vessel density on day 21 after Ab injection
To evaluate vessel density, we employed a microangiographic technique that was developed recently. 19 In brief, FITC-albumin solution was prepared by dissolving bovine desiccated albumin-FITC (Sigma-Aldrich, St Louis, MO, USA) in phosphate-buffered saline (500 mg per 50 ml). Mice were deeply anesthetized and then perfused transcardially with FITC-albumin solution at a rate of 1 ml min À1 (10 ml kg
À1
). The brain was removed, fixed in 10% formalin solution and cut on a cryostat at 30 mm. Two consecutive sections were obtained from each mouse brain and observed with a microscope. For quantification, the region of interest was set as the dentate gyrus in the hippocampus. Images were observed using a fluorescence microscope (PROVIS AX80; Olympus, Tokyo, Japan). The acquired images were imported and analyzed by Image J.
Detection of superoxide anion in brain sections on day 21 after Ab injection Superoxide anion was detected as described previously. 23 In brief, frozen, enzymatically intact, 30-mmthick sections were prepared from mouse brain and immediately incubated with DHE (10 mol l À1 ; Probes Inc., Eugene, OR, USA) in phosphate-buffered saline for 30 min at 37 1C in a humidified chamber. DHE is oxidized on reaction with superoxide to ethidium, which binds to DNA in the nucleus and fluoresces red. Images were observed using a fluorescence microscope (PROVIS AX80; Olympus). The intensity of the fluorescence was analyzed and quantified using Image J.
Immunohistochemical study
To analyze the localization of HGF expression, mouse brains were freshly frozen. Then, 10-mm-thick sections were prepared and fixed in U-Fix (Sakura Finetek, Tokyo, Japan). Sections were blocked with goat serum and incubated with anti-HGF antibody (Santa Cruz, Santa Cruz, CA, USA) according to the manufacturer's recommended concentration. After rinsing with phosphate-buffered saline, sections were treated using an ABC kit (Vecstain, Burlingame, CA, USA). To evaluate the synaptic activity of neurons, 10-mm-thick sections were prepared and incubated with anti-synaptophysin antibody (Abcam, Cambridge, UK) according to the manufacturer's recommended concentration. All images were observed using a fluorescence microscope (PROVIS AX80; Olympus). Quantitative analysis of images was performed using Image J.
Quantitative histological analysis
To quantify FITC-albumin, DHE staining and synaptophysin staining, the acquired images were imported into Adobe Photoshop (version 7.0, Adobe System, San Jose, CA, USA). These were imported into Image J (version 1.32, NIH, USA). The region of interest was set as the dentate gyrus in the hippocampus for quantification of FITC-albumin staining or DHE staining. The threshold of signal was fixed and the fluorescence ratio was calculated by the equation % area ¼ (number of high signal pixels)/(total number of pixels).
Measurement of BDNF
Brain-derived neurotrophic factor (BDNF) was measured by sandwich enzyme-linked immunosorbent assay. We used a chemikine BDNF sandwich ELISA kit (Chemicon, Temecula, CA, USA). Briefly, a brain sample was obtained from the whole brain, and 150 mg of the brain sample was dounce homogenized (6 strokes) in 1.5 ml of ice-cold homogenization buffer consisting of 100 mM Tris-HCl, pH 7.0, containing 2% bovine serum albumin, 1 M NaCl, 4 mM EDTA-2Na, 2% Triton X-100, 0.1% sodium azide and the protease inhibitors (SigmaAldrich) 5 mg ml À1 aprotinin, 0.5 mg ml À1 antipain, 157 mg ml À1 benzamidine, 0.1 mg ml À1 pepstain A and HGF gene therapy for Ab-induced cognitive impairment D Takeuchi et al 17 mg ml À1 phenylmethylsulpfonyl fluoride. Homogenates were centrifuged at 14 000 g for 30 min. The supernatant was used for the BDNF assay, according to the manufacturer's instructions.
Measurement of HGF
Hepatocyte growth factor was measured by enzymelinked immunosorbent assay. We used an IMMUNIS human HGF EIA kit (Institute of Immunonology Co., Ltd, Tokyo, Japan) for human HGF measurement and an IMMUNIS rat HGF EIA kit (Institute of Immunology Co., Ltd) for mouse HGF measurement. The IMMUNIS rat HGF EIA kit shows the same reactivity with mouse HGF, and crossreacts with human HGF with about 4% crossreactivity. Briefly, brain samples were obtained from the whole brain, and 150 mg of the brain sample was disintegrated with IMMUNIS HGF extraction buffer (Institute of Immunology Co., Ltd) using a Multi-beads shocker (Yasui Kikai, Osaka, Japan) at 2000 g for 15 s. Homogenates were centrifuged at 14 000 g for 30 min. The supernatant was used for the HGF assay, according to the manufacturer's instructions.
Quantitative real-time reverse transcription-PCR
Total RNA was prepared from frozen hippocampal samples, using RNeasy Lipid Tissue Mini (Qiagen), according to the manufacturer's instructions. One microgram of total RNA was reverse transcribed into first strand cDNA with an OligodT Primer using SuperScript III reverse transcriptase (Invitrogen, Carlsbad, CA, USA). The levels of mRNA expression were quantified by realtime reverse transcription-PCR using SYBR Premix Ex Taq (TaKaRa, Shiga, Japan). Thermal cycler parameters included a 1 min step at 95 1C, followed by 40 cycles of a 12 s step at 95 1C and a 1 min step at 60 1C for mouse c-Met, mouse HGF, human HGF and mouse glyceraldehyde-3-phosphate dehydrogenase, a 3 min step at 94 1C, 
Statistical analysis
All values are expressed as mean±s.e.m. Analysis of variance was used to determine the significance of differences in multiple comparisons. Po0.05 was considered significant.
